论文部分内容阅读
非乙醇性脂肪性肝病已成为一种常见的危害人类健康的疾病,早期可以仅出现肝细胞脂肪变性,进一步可发展为脂肪性肝炎、肝纤维化、肝硬化等终末期病变。胰岛素抵抗和氧化应激在非乙醇性脂肪性肝病的发病机制中有重大意义,大量实验表明,减轻胰岛素抵抗和抗氧化剂治疗非乙醇性脂肪性肝病有效。此外,降脂药物、细胞保护剂等对肝脏病理及血清学指标也有改善,目前尚未发现治疗非乙醇性脂肪性肝病的特效药物。
Non-alcoholic fatty liver disease has become a common disease that endangers human health. In the early stage, only fatty degeneration of liver cells may occur, and further development of end-stage disease such as steatohepatitis, hepatic fibrosis and cirrhosis may occur. Insulin resistance and oxidative stress are of great importance in the pathogenesis of nonalcoholic fatty liver disease. Numerous experiments show that reducing insulin resistance and antioxidants are effective in treating non-alcoholic fatty liver disease. In addition, lipid-lowering drugs, cytoprotective agents and other liver pathology and serological indicators have improved, so far no special drugs for the treatment of non-alcoholic fatty liver disease.